Insider trade

Director sold ~$228K of ARWR shares in the open market

Traded May 12, 2026 · Filed May 14, 2026

Why it stands out

A board member of Arrowhead Pharmaceuticals sold $228K of Arrowhead Pharmaceuticals shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$228,334

Shares × reported transaction price

Timing vs results

5 days after results of May 7, 2026, 84 days before results of Aug 4, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−2.2%	+0.9%	−3.1%
30 days	+0.6%	+2.1%	−1.5%
90 days	+11.6%	+5.2%	+6.4%

Past results only. Not a forecast.

Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Scheduled in advance6mo ago

Scheduled in advance6mo ago

Scheduled in advance6mo ago